Drug Profile
Amiloride/spironolactone - Hemodynamic Therapeutics
Alternative Names: amiloride hydrochloride/spironolactone; HTI-101; spironolactone/amiloride; spironolactone/amiloride-hydrochlorideLatest Information Update: 14 Sep 2017
Price :
$50
*
At a glance
- Originator University of Alabama
- Class Antihormones; Antihypertensives; Lactones; Pregnenes; Pyrazines; Small molecules
- Mechanism of Action Aldosterone antagonists; Potassium-sparing diuretics; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Resistant hypertension
Most Recent Events
- 14 Sep 2017 Chemical structure information added
- 03 Aug 2015 No recent reports on development identified - Phase-II for Resistant hypertension in USA (PO)
- 14 Dec 2009 HTI 101 is available for collaboration for development and commercialisation (http://www.hemodynamictx.com)